Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion type Assertion NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_head.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion description "[When using retroviral-vector-based gene therapy, wild-type LTR vectors should be employed to target TP53-defective tumors, whereas thyroid-specific promoters should be used for transcriptional targeting of thyroid carcinomas carrying wild-type TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_provenance.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion evidence source_evidence_literature NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_provenance.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion SIO_000772 15650765 NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_provenance.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion wasDerivedFrom befree-2016 NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_provenance.
- NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_assertion wasGeneratedBy ECO_0000203 NP476307.RAUoHwy0rmw5lMYVNpZ6gGSZCqHgFsnJ9s4Kb6-T0UxLo130_provenance.